The fund is the corporate venture arm of an Australian-based company with an interest in infection prevention technology, primarily in the hospital setting. The firm is interested in strategic investments and acquisitions, spanning benchtop proof of concept to businesses selling products into the market. Within the area of infection prevention and control, the fund will consider digital health, diagnostics and medical device technologies that relate to infection, but will not invest in pharmaceutical therapeutics. Investments can range from less than $1M, up to enterprise scale acquisitions. The firm will invest globally.
The firm has a focus on digital health, diagnostics and medical device technologies that address infection prevention and control, with a focus on healthcare acquired infection.
The fund will only make strategic investments that align with the corporate vision. The firm is an active investor, and will typically take a board seat after investing.
If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.
A Japanese pharmaceutical company is dedicated to research, development, and commercialization of innovative products for unmet medical needs in the areas of musculoskeletal disorders, including pain management and critical care. The company is vastly investing to expand their presence from its domestic roots in Japan to become a Global Specialty Pharma. To achieve above goal, the company is looking for opportunities of early stage pipelines and/or research collaborations with global rights to expand their business worldwide.
The company Is pursuing attractive, new in-licensing and research collaboration opportunities in the following areas of interest: in relation to in-licensing opportunities in pre-clinical stage for the global market, the company is interested in chronic pain, inflammatory diseases (including rheumatoid arthritis), critical care, and muscle-related disorders (i.e. DMD, ALS, etc.) In relation to research collaboration opportunities for the global market, the company is interested in drug seeds for chronic pain, inflammatory diseases (including rheumatoid arthritis), critical care, as well as platform technologies related to drug delivery, formulation, excipients, oral, transdermal, nanoparticle, controlled release, and targeting.
The firm has no specific company or management team requirements and is willing to work with all early-stage companies globally, with promising technologies. The firm will seek global rights.
If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.
By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN
Digital Redefining Early Stage Investments (RESI) June ended on a high note last week, again providing a valuable platform for early-stage life science companies and investors/strategic partners to connect and start dialogue.
This RESI also featured the largest number of Innovator’s Pitch Challenge companies, with almost fifty companies participating. Each company was assigned to one of ten live Q&A sessions featuring investors and industry partners, based on sector/technology.
Attendees voted for their favorite companies throughout the three days of the conference. Check out the winners below!
Throne is an American therapeutics company aimed at commercializing a novel stem cell technology that can fundamentally reverse diabetes, alopecia areata and other autoimmune diseases through immune education. The patented technology is recognized as the leading “practical cure project” for type 1 diabetes among 594 global projects (JDCA 2020). Stem Cell Educator therapy is a single dialysis-like treatment that fundamentally “resets” a patient’s immune system and corrects the underlying autoimmunity. 200+ patients between the ages of 3 and 70 have been treated in 10 years of clinical research in Spain, China, and US. 70% of type 1 and type 2 diabetic patients demonstrated clinical efficacy. Many patients reduced insulin dosing and some have become insulin independent. This technology has been successfully tried in more than 10 autoimmune diseases including alopecia, lupus, fibrosis, and scleroderma. This therapy is ready to use and is approved to begin three FDA phase 2 clinical trials (type 1 diabetes, alopecia areata, COVID-19). Throne is looking to raise $5M to complete US FDA phase 2 through to commercialization. Throne is open to partnerships, joint ventures, investments, and license arrangements.
Praetego is a pre-clinical stage pharmaceutical company with a mission to improve the health and longevity of diabetic patients. Praetego is developing novel small molecules (Amadorins) to alleviate serious diabetic complications, starting with peripheral neuropathy. Amadorins are first-in-class molecules able to inhibit a primary driver of diabetic microvascular disease and are derived from a clinically proven prototype.
A proprietary drug delivery nanotechnology that generates poorly soluble drugs as nanoparticles for better bioavailability. Our NanoTransformer(TM) technology can generate drug nanoparticles through phase transfer method without using any chemicals or solvent. We work with (1) preclinical stage drug developers for animal study formulations and (2) innovative generic companies for generic nanodrug development. We are at revenue stage and our revenue forecast is $150M in 2026 (our target exit time frame).
Congratulations to each of the winners, who have received free tickets to future RESI conferences to boost their fundraising efforts. Thank you to all finalists, judges, and attendees who make the IPC an exciting and powerful part of RESI! Interested in joining a future IPC? Applications are open for RESI Partnering Week September, featuring three separate RESI conferences! Select the logos below to learn more!
By Rory McCann, Marketing Manager & Conference Producer, LSN
RESI Partnering Week returns September 13-17 and attendees can save $100 when they register by July 9! RESI Partnering Week is a five-day digital partnering experience connecting early-stage entrepreneurs in drugs, devices, diagnostics, and digital health with active investors who are a fit for their product and stage of development.
The RESI creators at Life Science Nation (LSN) understand that partnering is a multi-faceted process that takes time and commitment to yield fruitful relationships that turn into strategic partnerships. We offer several programs for attendees to take advantage of in order to optimize their experience, including our interactive panels that feature prominent life science and healthcare investors, as well as fundraising executives with their own tales from the road.
Angels & Family Offices
Asia Cross Border
Big Pharma
Corporate VC
Medical Devices
Mental & Behavioral Health
Seed Funds
Tales from the Road
Healthcare Communications
Reproductive Wellness
Healthcare Systems and Infrastructure
Accelerated Pharmaceutical Development
Diagnostic Wearables
Precision Medicine
Social Isolation & Loneliness
Health & Home Care
Medical Accountability & Adherence
Sensory Wellness
Contact us to learn more about RESI Partnering Week and how we can tailor the experience to meet your partnering needs.
For a demo, or to see how many investors in our a database are interested in your product, feel free to schedule a time that works best for you via LSN BD team’s Calendly link below.
By Elizabeth Murphy, Manager of Business Development, LSN
Service Provider Showcase participant, Amarex Clinical Research joined Digital RESI on June 8-10 by hosting a dynamic workshop on Expediting U.S. FDA Submissions/Trial Initiations and Acceptance of Foreign Data by the U.S. FDA. The Amarex team put on a well-attended workshop helping early-stage entrepreneurs navigate the often-complicated processes working with the FDA. Of their experience with Digital RESI, the team said, “This virtual conference provided Amarex a fantastic opportunity to present in front of leading venture capitalists and pharma/biotech startups on top strategies to get products through the FDA clinical trials approval process. “
As a sponsor of the event, Amarex’s content received prominent placement on the 3-day event agenda, but also the partnering platform. Newcomers to the Digital RESI experience, the Amarex team said, “RESI’s platform provides the life sciences industry with innovative ways to network through their partnering program, allowing our team members to build new relationships with key executives. We look forward to participating in future RESI events.”
Digital RESI returns in September, as a part of RESI Partnering Week, alongside RESI AI and RESI Longevity. Learn more about the 5-day partnering experience and how your organization can take part in the sponsorship opportunities, reach more clients, and help them reach their goals.
For a demo, or to see how many investors in our a database are interested in your product, feel free to schedule a time that works best for you via LSN BD team’s Calendly link below.
An investment firm based in the USA manages corporate venture funds of a large health system and looks to invest in companies of strategic interest to its major health plan investors while seeking strong financial returns. With the fund, the firm is looking to make investments ranging from $1 – $20 million over the lifetime of the investment in stages ranging anywhere from seed to buyout. The firm is actively reviewing new opportunities and will consider companies located around the globe. The firm also manages other funds that seek to invest in food and agriculture companies and insurtech companies, respectively.
Within the healthcare space, the firm looks to invest in sectors of Healthcare IT, Services, Diagnostics, and Devices.
The firm is looking for companies with experienced management teams and prefers working with complete teams although they also have experience and are willing to work with incomplete management teams as well. The firm is looking for privately held companies and is open to either lead or co-invest in rounds. The firm generally looks to take a board seat following an investment.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
A seed fund in collaboration with a major China venture capital firm manages over $1B has both USD funds and CNY funds. The firm has invested in over 700 portfolio companies, including over 60 life science companies. While open to growth stage companies, the firm prefers to get involved as early as possible, and ideally be the first institutional investor for its portfolio company. Initial sizes of investment can largely vary, but a typical allocation size is between $1 MM to $2 MM. The firm is very entrepreneurs friendly, and invests in companies across the globe.
The firm has a general interest in Therapeutics, Digital Health, MedTech, and Diagnostics.
The firm believes that great businesses start with exceptional founding teams and values the management team of a start-up more than anything else. The firm prefers companies with a Chinese angle.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
